DE60106905D1 - Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp - Google Patents

Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp

Info

Publication number
DE60106905D1
DE60106905D1 DE60106905T DE60106905T DE60106905D1 DE 60106905 D1 DE60106905 D1 DE 60106905D1 DE 60106905 T DE60106905 T DE 60106905T DE 60106905 T DE60106905 T DE 60106905T DE 60106905 D1 DE60106905 D1 DE 60106905D1
Authority
DE
Germany
Prior art keywords
formulations
cell phenotype
malignant cell
nitrogen monoxide
mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60106905T
Other languages
English (en)
Other versions
DE60106905T2 (de
Inventor
A Adams
H Graham
Jeremy P W Heaton
Lynne-Marie Postovit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Cellegy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharmaceuticals Inc filed Critical Cellegy Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60106905D1 publication Critical patent/DE60106905D1/de
Publication of DE60106905T2 publication Critical patent/DE60106905T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
DE60106905T 2000-04-26 2001-04-26 Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp Expired - Lifetime DE60106905T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19975700P 2000-04-26 2000-04-26
US199757P 2000-04-26
US27746901P 2001-03-21 2001-03-21
US277469P 2001-03-21
PCT/CA2001/000566 WO2001080890A2 (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Publications (2)

Publication Number Publication Date
DE60106905D1 true DE60106905D1 (de) 2004-12-09
DE60106905T2 DE60106905T2 (de) 2005-12-01

Family

ID=26895114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60106905T Expired - Lifetime DE60106905T2 (de) 2000-04-26 2001-04-26 Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp

Country Status (12)

Country Link
US (1) US6946484B2 (de)
EP (1) EP1278547B1 (de)
JP (1) JP2003531179A (de)
AT (1) ATE281177T1 (de)
AU (2) AU5022101A (de)
CA (1) CA2407466C (de)
DE (1) DE60106905T2 (de)
ES (1) ES2232613T3 (de)
HK (1) HK1052468B (de)
IL (2) IL152428A0 (de)
MX (1) MXPA02010551A (de)
WO (1) WO2001080890A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
CA2478145A1 (en) * 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
JP5564157B2 (ja) 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 心臓血管状態の処置のための亜硝酸塩の使用方法
EP2348114B1 (de) 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Konjugate zur Zuführung an Knochen und Verfahren zu deren Verwendung beim Hinführen von Proteinen zum Knochen
SE0401871D0 (sv) * 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
WO2006125123A2 (en) 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
WO2006128121A2 (en) 2005-05-27 2006-11-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20070172847A1 (en) * 2005-11-15 2007-07-26 The Regents Of The University Of California Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
US20070202155A1 (en) * 2006-02-03 2007-08-30 Cure Therapeutics, Inc. Low dose no donor-containing transdermal patch
WO2007123777A2 (en) * 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US20070259026A1 (en) * 2006-04-20 2007-11-08 Robert Ang Vasodialating dressing for use with intravenous catheters
US8766512B2 (en) * 2009-03-31 2014-07-01 Sand 9, Inc. Integration of piezoelectric materials with substrates
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
JP5948683B2 (ja) * 2011-02-28 2016-07-06 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
USD974802S1 (en) * 2013-06-16 2023-01-10 Bengt Johansson Flooring guard for pets
USD949597S1 (en) 2014-06-15 2022-04-26 Bengt Johansson Flooring guard for pets
USD975470S1 (en) * 2014-06-15 2023-01-17 Bengt Johansson Flooring guard for pets
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
EP3195168B1 (de) * 2014-07-31 2022-09-07 The University Of Western Australia Verfahren zur identifizierung von immuntherapiearzneimittelkombinationen unter verwendung eines netzwerkansatzes
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CN109152820A (zh) 2016-04-01 2019-01-04 阿雷克森制药公司 用碱性磷酸酶治疗肌肉无力
WO2017190091A1 (en) 2016-04-29 2017-11-02 Vindico Nanobiotechnology, Llc Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
EP3782618A4 (de) * 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. Verfahren zur vorbeugung oder behandlung von nebenwirkungen einer krebstherapie

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5840759A (en) * 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
EP0722320B1 (de) * 1993-10-08 2000-07-19 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
US5700830A (en) * 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
LV11542B (en) 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US5849790A (en) 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
DE19732323C2 (de) * 1996-08-06 1999-08-19 Dunzendorfer Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
EP2292630B1 (de) 1996-09-27 2015-11-25 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services O2-substituierte 1-(2-carboxylato)pyrrolidin-1-yl Diazen-1-ium-1,2-Diolate
AU8398398A (en) 1997-07-14 1999-02-10 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
AU1770299A (en) 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
CA2330628A1 (en) 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
AU2900100A (en) 1999-03-05 2000-09-21 Merck Frosst Canada & Co. Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
AU2001234602A1 (en) 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
SE0000303D0 (sv) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
WO2001070199A1 (en) 2000-03-20 2001-09-27 Novovascular, Inc. Matrices containing nitric oxide donors and reducing agents and their use
US20010038832A1 (en) 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
US6656966B2 (en) 2000-06-22 2003-12-02 Nitromed, Inc. Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
DE60106905T2 (de) 2005-12-01
ES2232613T3 (es) 2005-06-01
US6946484B2 (en) 2005-09-20
WO2001080890A2 (en) 2001-11-01
HK1052468A1 (en) 2003-09-19
EP1278547A2 (de) 2003-01-29
ATE281177T1 (de) 2004-11-15
IL152428A0 (en) 2003-05-29
JP2003531179A (ja) 2003-10-21
HK1052468B (zh) 2005-06-03
CA2407466A1 (en) 2001-11-01
AU5022101A (en) 2001-11-07
WO2001080890A3 (en) 2002-08-08
EP1278547B1 (de) 2004-11-03
CA2407466C (en) 2010-11-02
IL152428A (en) 2011-06-30
US20020040059A1 (en) 2002-04-04
AU2001250221B2 (en) 2006-07-06
MXPA02010551A (es) 2003-09-25

Similar Documents

Publication Publication Date Title
DE60106905D1 (de) Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
ATE499098T1 (de) Verwendung von parp-1-hemmern
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
BR9707233A (pt) Fenantridinas
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
YU48701A (sh) Fenilfenantridini sa dejstvom inhibicije pde-iv
GB2368283A (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
MXPA02011411A (es) Inhibidores de proteasa de serina.
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
PT998460E (pt) Novos derivados de tetrazole
TR200003159T2 (tr) Antipicornaviral bileşikler, hazırlanışları ve kullanımları
DE60105418D1 (de) Serinprotease-inhibitoren
ATE319718T1 (de) Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
ATE294793T1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
DE59909760D1 (de) Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
ATE315029T1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
TR200201150T2 (tr) Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.
GEP20074075B (en) Indazolamides with analgesic activity
DE69628743D1 (de) Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen
ATE284220T1 (de) Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode
AU6986201A (en) Renal regulatory elements and methods of use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: QUEEN'S UNIVERSITY AT KINGSTON, KINGSTON, ONTARIO,